Alzamend Neuro, Inc.
ALZN
$0.68
-$0.0206-2.94%
NASDAQ
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 590.30K | 1.05M | 755.80K | 666.60K | 751.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.04M | 1.36M | 962.40K | 850.10K | 2.66M |
| Operating Income | -1.04M | -1.36M | -962.40K | -850.10K | -2.66M |
| Income Before Tax | -1.04M | -1.36M | -974.40K | -851.50K | -2.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.04M | -1.36M | -974.40K | -851.50K | -2.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.04M | -1.36M | -974.40K | -851.50K | -2.66M |
| EBIT | -1.04M | -1.36M | -962.40K | -850.10K | -2.66M |
| EBITDA | -1.02M | -1.35M | -949.70K | -837.40K | -2.65M |
| EPS Basic | -0.19 | -0.40 | -1.25 | -1.24 | -3.77 |
| Normalized Basic EPS | -0.12 | -0.24 | -0.78 | -0.77 | -2.36 |
| EPS Diluted | -0.19 | -0.40 | -1.25 | -1.24 | -3.77 |
| Normalized Diluted EPS | -0.12 | -0.24 | -0.78 | -0.77 | -2.36 |
| Average Basic Shares Outstanding | 5.52M | 3.53M | 777.80K | 688.20K | 705.40K |
| Average Diluted Shares Outstanding | 5.52M | 3.53M | 777.80K | 688.20K | 705.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |